Neurocrine Biosciences
NBIX
$113.11
Share price
-1.11%
Change (1 day)
20.25%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
Neurocrine Biosciences (NBIX) - Cash on Hand
Cash on Hand as of June 2023 : $0.97 B
According to Neurocrine Biosciences
's latest financial reports the company has $0.97 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Neurocrine Biosciences - Cash on Hand chart (from 2001 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $0.98 B | 39.08% |
| 2021-12-31 | $0.71 B | -11.2% |
| 2020-12-31 | $0.80 B | 19.46% |
| 2019-12-31 | $0.67 B | 3.01% |
| 2018-12-31 | $0.65 B | 26.16% |
| 2017-12-31 | $0.51 B | 67.86% |
| 2016-12-31 | $0.30 B | -18.95% |
| 2015-12-31 | $0.37 B | 95.65% |
| 2014-12-31 | $0.19 B | 32.98% |
| 2013-12-31 | $0.14 B | -15.76% |
| 2012-12-31 | $0.17 B | 34.01% |
| 2011-12-31 | $0.12 B | 1.76% |
| 2010-12-31 | $0.12 B | 137.29% |
| 2009-12-31 | $53.46 M | -33.56% |
| 2008-12-31 | $80.47 M | -55.14% |
| 2007-12-31 | $0.17 B | -1.76% |
| 2006-12-31 | $0.18 B | -33.13% |
| 2005-12-31 | $0.27 B | -9.32% |
| 2004-12-31 | $0.30 B | -33.55% |
| 2003-12-31 | $0.45 B | 85.19% |
| 2002-12-31 | $0.24 B | -23.52% |
| 2001-12-31 | $0.31 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $19.97 B | 1,944.84% | 🇺🇸 USA |
 AbbVie ABBV | $6.72 B | 588.24% | 🇺🇸 USA |
 Eli Lilly LLY | $2.82 B | 189.66% | 🇺🇸 USA |
 Repligen
RGEN | $0.60 B | -38.19% | 🇺🇸 USA |
 Athersys ATHX | $1.8 M | -99.82% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | $0.16 B | -83.44% | 🇺🇸 USA |
 Palatin Technologies PTN | $19.63 M | -97.99% | 🇺🇸 USA |
 Royalty Pharma RPRX | $2.90 B | 197.75% | 🇬🇧 UK |